References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A.
Global cancer statistics 2018: GLOBOCAN estimates of incidence and
mortality worldwide for 36 cancers in 185 countries. CA Cancer J
Clin. 2018;68 (6):394-424.
2. Tsikouras P, Zervoudis S, Manav B, et al. Cervical cancer: screening,
diagnosis and staging. Journal of BUON. 2016;21(2):320-325.
3. Sung HA-O, Ferlay J, Siegel RA-O, et al. Global Cancer Statistics
2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36
Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249.
4. Torre LA, Bray F, Siegel RL, J F, J L-T, A J. Global cancer
statistics, 2012. CA: A Cancer Journal for Clinicians.2012;65(2):87-108.
5. Torre LA, Siegel RL, Ward EM, Jemal A. Global Cancer Incidence and
Mortality Rates and Trends–An Update. Cancer Epidemiol
Biomarkers Prev. 2016;25(1):16-27.
6. Crowley FJ, O’Cearbhaill RE, Collins DC. Exploiting somatic
alterations as therapeutic targets in advanced and metastatic cervical
cancer. Cancer Treat Rev. 2021;Jul(98):102225.
7. Wardak S. Human Papillomavirus (HPV) and cervical cancer. Med
Dosw Mikrobiol. 2016;2016;68(1):73-84.
8. Passamonti B, Gustinucci D, Giorgi Rossi P, et al. Cervical human
papilloma virus (HPV) DNA primary screening test: Results of a
population-based screening programme in central Italy. J Med
Screen. 2017;24(3):153-162.
9. TA. G. Global Call for Action Towards the Elimination of Cervical
Cancer. 2019;Vol 2019.( Geneva, Switzerland: World Health Organization;
2018.).
10. Trimble L, Morrow MP, Kraynyak KA, et al. Safety, efficacy, and
immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine
targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical
intraepithelial neoplasia 2/3: a randomised, double-blind,
placebo-controlled phase 2b trial. Lancet.2015;386(10008):2078-2088.
11. Grimm C, Polterauer S, Natter C, et al. Treatment of cervical
intraepithelial neoplasia with topical imiquimod: a randomized
controlled trial. Obstet Gynecol. 2012;120(1):152-159.
12. Kone PA, Wang L, Gao J, R K. Are Women Who Exit Colposcopy Without
Treatment at Elevated Risk for Cervical Cancer? J Low Genit Tract
Dis. 2017;21(1):47-54.
13. Gu YY, Zhou GN, Wang Q, Ding JX, Hua KQ. Evaluation of a methylation
classifier for predicting pre-cancer lesion among women with abnormal
results between HPV16/18 and cytology. Clinical Epigenetics.2020;12(1):57.
14. Fang J, Zhang H, Jin S. Epigenetics and cervical cancer: from
pathogenesis to therapy. Tumour Biol. 2014;35(6):5083-5093.
15. Wentzensen N, Sun C, Ghosh A, et al. Methylation of HPV18, HPV31,
and HPV45 genomes and cervical intraepithelial neoplasia grade 3.Journal of the National Cancer Institute. 2012;204(22):1738-1749.
16. Tian Y, Yuan W, Liou YL, et al. Utility of gene methylation
analysis, cytological examination, and HPV-16/18 genotyping in triage of
high-risk human papilloma virus-positive women. Oncotarget.2018;8(37):62274-62285.
17. Schmitz MA-Ohoo, Eichelkraut K, Schmidt D, et al. Performance of a
DNA methylation marker panel using liquid-based cervical scrapes to
detect cervical cancer and its precancerous stages. BMC Cancer.2018;18(1):1471-2407.
18. Schmitz M, Wunsch K, Hoyer H, et al. Performance of a methylation
specific real-time PCR assay as a triage test for HPV-positive women.Clin Epigenetics. 2017;9(118).
19. Wilting SM, van BR, Henken F, et al. Methylation-mediated silencing
and tumour suppressive function of hsa-miR-124 in cervical cancer.Molecular Cancer. 2010;2010 Jun 26;9:167.
20. Rogeri CD, Silveira HCS, Causin RL, et al. Methylation of the
hsa-miR-124, SOX1, TERT, and LMX1A genes as biomarkers for precursor
lesions in cervical cancer. Gynecol Oncol. 2018;150(3):545-551.
21. Clarke M, Luhn P, Gage JC, et al. Discovery and validation of
candidate host DNA methylation markers for detection of cervical
precancer and cancer. International Journal of Cancer.2017;141(4)(4):701-710.
22. Heichman KA, Warren JD. DNA methylation biomarkers and their utility
for solid cancer diagnostics. Clinical chemistry and laboratory
medicine 2012;50(10):1707-1721.
23. Saavedra KP, Brebi P, Roa JC. Epigenetic alterations in
preneoplastic and neoplastic lesions of the cervix. Clin
Epigenetics. 2012;4(1):13.
24. Lorincz A, Brentnall A, Vasiljevic N, et al. HPV16 L1 and L2 DNA
methylation predicts high-grade cervical intraepithelial neoplasia in
women with mildly abnormal cervical cytology. International
Journal of Cancer. 2013;133(3):637-644.
25. Hesselink AT, Heideman Da Fau - Steenbergen RDM, Steenbergen Rd Fau
- Coupe VMH, et al. Combined promoter methylation analysis of CADM1 and
MAL: an objective triage tool for high-risk human papillomavirus
DNA-positive women. Clinical Cancer Research.2011;15(17):2459-2465.
26. Vink FJ, Meijer CJ, Clifford GM, et al. FAM19A4/miR124-2 methylation
in invasive cervical cancer: A retrospective cross-sectional worldwide
study. International Journal of Cancer. 2019;Aug 7:[Epub ahead
of print].
27. De SL, Berkhof J, Steenbergen RD, et al. Cervical cancer risk in
HPV-positive women after a negative FAM19A4/mir124-2 methylation test: A
post hoc analysis in the POBASCAM trial with 14 year follow-up.International Journal of Cancer. 2018;143(6):1541-1548.
28. Lai HC, Chen T-C, Huang H, et al. PAX1/SOX1 DNA methylation and
cervical neoplasia detection: a Taiwanese Gynecologic Oncology Group
(TGOG) study. Cancer Medicine. 2014;3(4):1062-1074.
29. Kong L, Wang L, Wang Z, et al. DNA methylation for cervical cancer
screening: a training set in China. Clin Epigenetics.2020;12(1):91.
30. Brentnall A, Vasiljevic N, Scibior-Bentkowska D, et al. HPV33 DNA
methylation measurement improves cervical pre-cancer risk estimation of
an HPV16, HPV18, HPV31 and {EPB41L3} methylation classifier.Cancer Biomark. 2015;15(5):669-675.
31. Hernandez-Lopez R, Lorincz A, Torres-Ibarra L, et al. Methylation
estimates the risk of precancer in HPV-infected women with discrepant
results between cytology and HPV16/18 genotyping. Clinical
Epigenetics. 2019;11(1):140.
32. Lorincz A, Brentnall AR, Scibior-Bentkowska D, et al. Validation of
a DNA methylation HPV triage classifier in a screening sample. Int
J Cancer. 2016;138(11):2745-2751.
33. Cook DA, Krajden M, Brentnall AR, et al. Evaluation of a validated
methylation triage signature for human papillomavirus positive women in
the HPV FOCAL cervical cancer screening trial. International
Journal of Cancer. 2019;144(10):2587-2595.
34. Ramírez AT, Sánchez GI, Nedjai B, et al. Effective methylation
triage of HPV positive women with abnormal cytology in a middle-income
country. Int J Cancer. 2021;148(6):1383-1393.
35. van VK, Poppe W, Verschuere H, Arbyn M. Pregnancy outcome after
cervical conisation: A 2nd retrospective cohort study in the Leuven
University Hospital. Eur J Obstet Gynecol Reprod Biol. 2017;2017
sep;216:224-231.
36. Loopik DL, Doucette S, Bekkers RLM, Bentley JR. Regression and
Progression Predictors of CIN2 in Women Younger Than 25 Years. J
Low Genit Tract Dis. 2016;20(3):213-217.